TLC to Present at Cantor Virtual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, September 11, 2020 – TLC (Nasdaq: TLC, TWO: 4152) announced that President George Yeh will participate in a fireside chat with analyst Kristen Kluska at the Cantor Virtual Global Healthcare Conference on September 15, 2020, at 10:00 AM ET. The discussion will focus on TLC's ongoing projects, including TLC599 for osteoarthritis pain relief, TLC590 for postsurgical pain, and TLC19 for COVID-19 treatment and prevention. A recording will be available on TLC's website.
- None.
- None.
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 11, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that George Yeh, President of TLC, will be discussing recent activities regarding the company in a fireside chat with Kristen Kluska, Research Analyst, at Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020 at 10:00am ET.
The 30-minute fireside chat will be a Q&A session in which Mr. Yeh will introduce TLC and talk about the company’s leading programs: TLC599 for sustained relief of osteoarthritis pain and TLC590 for sustained relief of postsurgical pain, and introduce TLC19 for prevention and treatment of COVID-19.
A recording of the fireside chat will be available on the company’s website at www.tlcbio.com in the Investors section, under News & Events.
About TLC
TLC (NASDAQ: TLC, TWO: 4152) is a clinical-stage specialty pharmaceutical company dedicated to the research and development of a diverse, wholly owned portfolio of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD™), including BioSeizer® sustained release technology and NanoX™ active drug loading technology, which are versatile in the choice of active pharmaceutical ingredients and scalable in manufacturing.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and involve a number of risks, assumptions, uncertainties and factors, including risks that the outcome of any clinical trial is inherently uncertain and product candidates may prove to be unsafe or ineffective, or may not achieve commercial approval. Other risks are described in the Risk Factors section of TLC’s annual report on Form 20-F for the year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on TLC’s expectations and assumptions as of the date of this press release. Actual results may differ materially from these forward-looking statements. Except as required by law, TLC expressly disclaims any responsibility to update any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.
FAQ
What will TLC discuss at the Cantor Virtual Global Healthcare Conference on September 15, 2020?
Who is participating in the fireside chat for TLC at the conference?
What time is TLC's presentation at the Cantor Virtual Global Healthcare Conference?
Where can I find the recording of TLC's fireside chat?
What are TLC's main products being discussed at the conference?
